|
|
name  click to compare prices |
» Shop local, ethical and at the best price on Ethishop  |
|
| |
|
Business & market
Subsidiaries
| shareholder | country | % | source |
|
country | address & contact : production type incentive source |
South Africa | Allergan Pharmaceuticals (Proprietary) Limited : Company |
Bermuda | Allergan Holdings B, Ltd. : Company |
Brazil | Allergan Produtos Farmacêuticos Ltda : Company |
Chile | Allergan Laboratorios Limitada : Company |
Colombia | Allergan de Colombia S.A : Company |
Ireland | Allergan Pharmaceuticals Holdings (Ireland) Limited : Company |
Ireland | Allergan Services International, Limited : Company |
Ireland | Allergan Sales, Limited : Company |
Ireland | Allergan Botox Limited : Company |
Mexico | Allergan, S.A. de C.V. : Company |
Monaco | Pharmac, S.A.M. : Company |
Singapore | Allergan Singapore Pte. Ltd : Company |
Thailand | Allergan (Thailand) Ltd. : Company |
Turkey | Allergan Optik Mamulleri Sanayi Ve Ticaret Limited : Company |
Venezuela | Allergan de Venezuela, S.A. : Company |
|
year name | photo position; compensation source |
| 2003Ball, F Michael |  Vice-president; salary: 0.73 million US$; stock-options: 0.48 million US$; Company |
| 2003Kaplan, Lester |  Vice-president; salary: 0.79 million US$; stock-options: 4.02 million US$; Company |
| 2002Brandt, Eric |  Chief Financial Officer; salary: 0.68 million US$; Company |
| 2002Pyott, David |  Chief Executive Officer; salary: 2.07 million US$; Company |
|
year | employees <> | social impact : country source |
| 2005 | -76 | Internal restructuring: | Les Echos |
|
year | employees <> | social impact : country source |
|
year |   | sales | income | | | source |
| 2003 |
| 1.77 | -0.05 | |   | billion US$ | Company |
| 2002 |
| 1.43 | 0.08 | |   | billion US$ | Company |
| 2001 |
| 1.75 | 0.22 | |   | billion US$ | Company |
| 2000 |
| 1.63 | 0.22 | |   | billion US$ | Company |
| 1999 |
| 1.45 | 0.19 | |   | billion US$ | Company |
| 1998 |
| 1.3 | -0.09 | |   | billion US$ | Company |
|
year | financial misdemeanor | sales | income | assets | buyback | source |
|
year | purpose : intermediary/lobby : institution source |
| 2000 | Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate translate | Washington Post |
|
year | purpose : intermediary/lobby : institution source |
|
|
|